|Home||Founder||What's New||In The News||Consulting|
Paradigm Shift Intervention Monitoring
Acknowledges trH3N2 Vaccine Development
As the viruses continue to evolve new SOIV candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at email@example.com or the institutions listed in announcements published on the WHO website.
The above comments are from the WHO update on pandemic vaccines, “Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness - September 2011,” which confirms that the sequences deposited at GISAID by the CDC are under pandemic trH3N2 development.
The report provides antigenic cross-reativities, which confirm the lack of protection offered by the seasonal H3N2 or pandemic H1N1 target in the current tri-valent vaccine, which was recently approved for the 2012 southern hemisphere and is identical to the targets approved for the 2010/2011 and 2011/2012 vaccine target for the northern hemisphere.
However, antisera against the trH3N2 vaccine target, MN/11/10, does cross react with the four recent 2011 isolates (IN/08/11, PA/09/11, PA/10/11, PA/11/11), although the description of trH3N2 cases in the United States is misleading.